术中替罗非班替代术前双联抗血小板用于血流导向术:病例系列与文献综述
血流导向术标准术前双联抗血小板治疗下弥散性缺血病灶发生率较高(通常55–65%)。本研究通过病例系列与文献综述,提供初步证据支持术中给予替罗非班作为标准术前双联抗血小板替代方案的安全性和有效性,可能减少操作相关缺血损伤。
要点
- 标准DAPT预处理下血流导向术后弥散缺血病灶发生率约55–65%
- 术中替罗非班或可替代术前DAPT,初步证据支持安全有效
- 该策略可能更高效实现血小板抑制并减少操作相关缺血损伤
核心结论
- 术中给予替罗非班作为标准术前双联抗血小板预处理的替代方案,初步证据支持其安全性和有效性。
研究设计与样本
- 病例系列研究结合文献综述,研究对象为接受血流导向术的患者。
主要发现
- 标准双联抗血小板预处理下血流导向术后弥散性缺血病灶发生率通常为55–65%。
- 不同患者及药物方案间血小板抑制水平差异很大,部分患者表现为超反应性。
临床怎么用
- 术中替罗非班可能作为术前双联抗血小板预处理的替代,用于血流导向术中的血小板抑制。
- 该策略可能减少操作相关缺血损伤并提高血小板抑制的效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Rates of diffusion lesions following flow diversion procedures are high (typically in the range of 55–65%) with standard dual antiplatelet pretreatment regimens. WHAT THIS STUDY ADDS The present study provides preliminary evidence supporting the safety and effectiveness of intraprocedural eptifibatide administration as an alternative to standard dual antiplatelet pretreatment. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY The use of intraprocedural eptifibatide may provide a more efficient means by which to achieve platelet inhibition during neuroendovascular procedures and may reduce procedure-related ischemic injury. Introduction Pretreatment with dual antiplatelet agents (DAPT) has been standard practice for patients undergoing aneurysm treatment with flow diversion to prevent periprocedural thromboembolic complications. The levels of platelet inhibition achieved with these agents have been shown to vary widely between patients and medication regimens. While some patients exhibit ‘super-responsiveness’,...
引用
- Journal of NeuroInterventional Surgery:Procedural eptifibatide administration as an alternative to preprocedural dual antiplatelet therapy for patients undergoing flow diversion procedures: case series and review of the literature
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。